We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Snibe Co.,Ltd.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) is a global leader in the IVD field, with 30 years o... read more Featured Products: More products

Download Mobile App





SNIBE Displays Super High Throughput CLIA Analyzer Powered by X Tech Technology

By LabMedica International staff writers
Posted on 21 May 2023

Snibe (Shenzhen, China) is showcasing its latest products with high-performance features at Euromedlab Roma 2023, including the newest member of its X-series of new-generation chemiluminescence immunoassay (CLIA) analyzers. More...

MAGLUMI X Tech is the core technology powering the X series of fully automatic CLIA analyzers which provide more efficient, convenient, and reliable immunology diagnostic solutions for laboratories and hospitals. The technology helps the X series analyzers deliver an amazing performance, higher accuracy, and further precision, while also making them affordable and easy to operate. The MAGLUMI X series offers three models to meet all types of demands. The small but smart MAGLUMI X3 is a small-footprint desktop analyzer having a throughput of 200 t/h, 20 reagent positions, and 72 sample positions to target for small- and mid-size laboratories and hospitals.

The most cost-effective analyzer and the newest member of the X-series - MAGLUMI X6 - with a higher throughput of up to 450 T/h offers up to 30 reagent positions and up to 112 sample positions, or up to 412 when integrated with a sample-storage module. The fastest analyzer in the X series - MAGLUMI X8 - is the most powerful CLIA analyzer that offers a super-high throughput of 600 t/h while ensuring the highest level of precision. It offers 42 reagent positions and 300 sample positions. MAGLUMI X8 can be integrated with the Biossays C8 to create the Biolumi CX8 biochemical and immunological integrated analyzer.

Aided by the incredible X Tech, the MAGLUMI X series CLIA analyzers possess even more powerful capabilities such as patented pipetting technology, accurate incubation technology, stable and precise measuring technology, multiple expansion solutions, and user-friendly and high-efficiency loading design. These latest high-end features help the MAGLUMI X series CLIA analyzers to provide better immunology diagnostic capabilities for laboratories and hospitals.

Related Links:
Snibe 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Drug Testing Assays
Atellica DT 250 Analyzer
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.